Forbion Entities Invest $64.8M in Braveheart Bio IPO and Convert Preferred Stock
BRVE is trading near its 52-week low of $28.465 (8.9% above the low) on light trading volume (0.3× avg).
Summary
Forbion entities, 10% owners of Braveheart Bio, bought $64.8 million in shares at the IPO price and converted Series A Preferred into common stock, reinforcing institutional confidence in the newly public company.
Key Events · Ownership and Investor Activity · BRVE
-
Forbion Purchases $64.8M in IPO
Forbion Growth Opportunities Fund III and Forbion Ventures Fund VII bought 3.6 million shares at $18.00, the IPO price, for a total of $64.8 million.
-
Series A Preferred Conversion
75 million shares of Series A Preferred Stock converted into 17.1 million common shares at a 1-for-4.38 ratio, eliminating the preferred overhang.
-
Post-Transaction Ownership
Forbion entities hold 11.64 million shares directly and 44.67 million shares indirectly through Forbion Ventures Fund VII, representing a significant stake in the newly public company.
-
IPO Context
The purchase occurred on the same day Braveheart Bio closed its upsized IPO, which raised $439.9 million after selling 24.44 million shares at $18.00.
Analysis · BRVE · Life Sciences
A powerful vote of confidence arrived on IPO day as Forbion Growth and Forbion Ventures—both 10% owners—purchased 3.6 million shares at the $18.00 offering price, deploying $64.8 million. Simultaneously, they converted 75 million shares of Series A Preferred into 17.1 million common shares, removing the preferred overhang and streamlining the capital structure. The move underscores deep institutional conviction at the deal price, coming as the company closed an upsized IPO that raised $439.9 million. While the purchase represents a substantial capital commitment from the funds, it firmly aligns a major pre-IPO backer with public shareholders.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRVE was trading at $31.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $28.47 to $32.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.